Episode 1, Part 3 of PharmTech AI Pulse Check covers why INTerpath-001's AI isn't ChatGPT and names pharma manufacturing's biggest AI governance gaps.
|Articles|June 2, 2016
- Pharmaceutical Technology-06-02-2016
- Volume 40
- Issue 6
Pharmaceutical Technology, June 2016 Issue (PDF)
Click the title above to open the Pharmaceutical Technology June 2016 issue in an interactive PDF format.
Advertisement
Articles in this issue
over 10 years ago
Modern Manufacturing Comes of Ageover 10 years ago
Examining Blow-Fill-Seal Technology for Aseptic Processesover 10 years ago
Demonstrating a State of Controlover 10 years ago
PAT: “Gateway Drug” to the 21st Century for the Pharma Industryover 10 years ago
Watch Out for the Hangoverover 10 years ago
Deciding When To Use Modular Constructionover 10 years ago
Integrating Single-Use Systems in Pharma Manufacturingover 10 years ago
Steps Closer to the Adoption of Continuous Processingover 10 years ago
Industry Moves Closer to Continuous ManufacturingAdvertisement
Related to this article
Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
FDA approves tavapadon, first D1/D5 agonist, validating AbbVie's $8.7B Cerevel deal and an October five-strength oral tablet launch.
Richard Jaenisch weighs how FDA's new NAM rule could reshape preclinical testing and what CMC teams should do now, on Manufacturing Intelligence.
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discuss the implementation of risk-based approaches for CMC.
Merck licenses SciBrunch's preclinical KRAS G12D inhibitor for $2.13B, raising tech transfer and scale-up questions for oral cancer drug development.
Ronald Piervincenzi, USP, urges drugmakers and purchasers to act on supply chain resilience to curb drug shortages and shape better policy.
Content on PharmTech.com this week ranged from fundamentals on the use of digital pathology in drug development, discussions on the use of AI in pharma, and regulatory actions impacting the industry.
Advertisement
Advertisement